Abstract: PROBLEM TO BE SOLVED A burdock fruit extract containing arctigenin at high content and its production method are provided, and both of which are used for treatment of pancreatic cancer. SOLUTION The burdock fruit extract containing arctigenin at high content by enzymatically converted arctiin into arctigenin with beta-glucosidase, which is an enzyme occurring endogenously in a burdock fruit, and adding ethanol, extracting, concentrating and then freeze-drying or spray drying.

Abstract: The present invention relates to a method for assessing a cancerous state of a mammal-derived specimen, which comprises: (1) a first step of measuring a methylation frequency of Neurofilament3 gene contained in a mammal-derived specimen or an index value having the correlation therewith, and (2) a second step of determining a cancerous state of the specimen based on a difference obtained by comparing the measured methylation frequency or the index value having the correlation therewith, with a control; and the like.

Abstract: The present invention provides a method for screening a patient to be administered with a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient, said method comprising collecting samples from patients who expresses an antigen which is recognized by the anti-cancer antibody, measuring cadherin function in the samples, and selecting a patient whose the cadherin function is decreased or deleted; a method for screening a patient who has a high efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient; and a method for improving an efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient.

Abstract: The present invention uses an RPN2 gene expression inhibitor as a cancer cell growth inhibitor, which further includes a drug showing an anti-cancer action if desired, and is administered in combination with atelocollagen if desired. In addition, the present invention is an anti-cancer agent including such cancer cell growth inhibitor.

Abstract: The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is useful for treatment of various diseases which highly expresses a polypeptide encoded by the PERP gene. Also, a polypeptide encoded by the PERP gene or a cell expressing the polypeptide can be specifically detected by an immunological method using the antibody, so that the antibody is useful for diagnosis of various diseases related to PERP.

Abstract: An antibody which binds to a polypeptide encoded by human PERP (p53 apoptosis effector related to PMP-22) gene which is considered to be related to incidence of cancer or the like is desired. The present invention provides a gene recombinant antibody which has no consensus sequence of an N-linked sugar chain in a variable region, specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by the PERP gene and binds to the extracellular region. The antibody is useful for treatment of various diseases expressing a polypeptide encoded by the PERP gene.

Abstract: The present invention relates to a method of concentrating low molecular weight peptides in the supernatant of serum-free cultured cells, said method comprising allowing the peptides to bind to a strong cation exchanger under an acid condition, and eluting them under an alkali condition to concentrate the peptide. Furthermore, peptides having the amino acid sequence as set forth in SEQ ID NO: 1 or 2, and a method of screening cancer markers using antibody to these peptides, are disclosed.

Abstract: The present invention relates to a method of concentrating low molecular weight peptides in the supernatant of serum-free cultured cells, said method comprising allowing the peptides to bind to a strong cation exchanger under an acid condition, and eluting them under an alkali condition to concentrate the peptide. Furthermore, peptides having the amino acid sequence as set forth in SEQ ID NO: 1 or 2, and a method of screening cancer markers using antibody to these peptides, are disclosed.

Abstract: The present invention relates to a method for assessing a cancerous state of a mammal-derived specimen, which comprises: (1) a first step of measuring a methylation frequency of Fibrillin2 gene contained in a mammal-derived specimen or an index value having the correlation therewith, and (2) a second step of determining a cancerous state of the specimen based on a difference obtained by comparing the measured methylation frequency or the index value having the correlation therewith, with a control; and the like.

Abstract: The present invention has for its subject to obtain a composition for preventing cancer efficient for preventing cancer or preventing cancer recurred after its therapy, or to obtain a pharmaceutical product, food and drink, and cosmetic having a function for preventing cancer. The present inventors found that a composition containing coenzyme Q has a cancer-preventive effect.

Abstract: An antibody which binds to a polypeptide encoded by human PERP (p53 apoptosis effector related to PMP-22) gene which is considered to be related to incidence of cancer or the like is desired. The present invention provides a gene recombinant antibody which has no consensus sequence of an N-linked sugar chain in a variable region, specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by the PERP gene and binds to the extracellular region. The antibody is useful for treatment of various diseases expressing a polypeptide encoded by the PERP gene.

Abstract: By analyzing hematopoietic stem cell proliferation regulators produced by stroma cells, a cDNA library is constructed and novel hematopoiesis-associated genes are isolated. Genes encoding the proteins as specified in the following (a) or (b): (a) having an amino acid sequence represented by one of SEQ ID NOS selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10 and 12; or (b) having an amino acid sequence derived from the amino acid sequence as defined in the above (a) by deletion, substitution or addition of one to several amino acids and having an activity of regulation hematopoietic stem cell proliferation.